sel. reversible cov. immunoproteosome inh.

oral efficacy (1 mpk) in xeno., Ph. I in MM

from SBDD

Mol. Cancer Ther., May 27, 2021

Merck KGaA, Darmstadt, DE

The Merck LMP7 inhibitor, M3258, is an orally available, selective, and reversible inhibitor of the immunoproteasome proteolytic subunit, LMP7. In contrast to the constitutive proteasome, the immunoproteasome is predominantly expressed…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.